SNCA

SNCA
Name	Alpha-synuclein
Uniprot	P37840
Chromosome	4q22.1
Aliases	PARK1, PARK4
Length	140 aa

SNCA is the gene encoding alpha-synuclein, a small neuronal protein central to research on Parkinsonian disorders and related synucleinopathies. First characterized through genetic linkage in familial Parkinsonism and biochemical isolation from Lewy bodies, alpha-synuclein links molecular genetics, neuropathology, and protein aggregation biology. Its study intersects work on protein misfolding, neurodegeneration, membrane biology, and proteostasis.

Gene and protein structure

The SNCA locus on chromosome 4q22.1 was identified by linkage studies involving families described in seminal reports like the PARK1 and PARK4 pedigrees; the gene spans multiple exons and produces transcripts with variable 5' and 3' untranslated regions. The 140–amino-acid alpha-synuclein protein contains an N-terminal amphipathic region with multiple imperfect KTKEGV repeats, a central hydrophobic non-amyloid-beta component (NAC) region critical for aggregation, and an acidic C-terminal tail enriched in proline and glutamate residues. Structural studies employed methods developed in labs led by investigators associated with the Salk Institute, University of Cambridge, and Massachusetts Institute of Technology using nuclear magnetic resonance and cryo-electron microscopy to reveal an intrinsically disordered monomer that adopts helical conformations upon binding to lipid vesicles. Familial missense mutations such as A53T, A30P, E46K and copy number variations reported in cohorts studied at institutions including Mayo Clinic, University College London, and Harvard Medical School alter folding, membrane affinity and aggregation propensity.

Expression and regulation

Expression of SNCA is highest in neuronal populations such as dopaminergic neurons of the substantia nigra pars compacta, presynaptic terminals, and certain cortical regions; expression patterns were characterized in atlases compiled by groups at the Allen Institute for Brain Science and projects like the Human Protein Atlas. Regulatory control involves promoter elements responsive to transcription factors studied in labs associated with National Institutes of Health and Cold Spring Harbor Laboratory, along with microRNAs identified in screens from institutions including Johns Hopkins University and University of Oxford. Epigenetic influences on SNCA expression, including DNA methylation changes and histone modifications reported in cohorts collected by consortia such as International Parkinson Disease Genomics Consortium, modulate risk. Alternative splicing, 5' and 3' UTR variants, and regulatory polymorphisms (e.g., REP1) discovered in collaborations including 23andMe cohorts affect transcript stability and protein levels.

Function and cellular roles

Alpha-synuclein localizes to presynaptic terminals where it participates in synaptic vesicle trafficking, SNARE-complex assembly, and neurotransmitter release, mechanisms elucidated in studies involving teams at Max Planck Institute for Neurobiology and Columbia University. It binds phospholipid membranes and curved vesicles, influencing vesicle docking and recycling; interactions with proteins such as synaptobrevin (VAMP2), synapsins, and CSPalpha were mapped by proteomics groups at European Molecular Biology Laboratory and Stanford University. Beyond synaptic roles, alpha-synuclein has been implicated in mitochondrial interaction and modulation of complex I activity in work from investigators at University of California, San Francisco and Mount Sinai. Cellular quality-control pathways including ubiquitin-proteasome and autophagy-lysosome systems, characterized by researchers at EMBL and University of Toronto, participate in turnover of alpha-synuclein.

Clinical significance and disease associations

Alterations in SNCA are causally linked to familial Parkinsonism described in clinical series from centers such as Mayo Clinic and University College London; point mutations and multiplications cause autosomal dominant parkinsonian syndromes with variable age at onset and progression. Aggregated alpha-synuclein is the major component of Lewy bodies and Lewy neurites observed in Parkinson's disease, Dementia with Lewy bodies, and multiple system atrophy cases diagnosed in neuropathology services at institutions including Johns Hopkins Hospital and Mayo Clinic Jacksonville. Genome-wide association studies led by consortia such as PDGene and International Parkinson Disease Genomics Consortium have identified SNCA as a major risk locus for sporadic Parkinson disease and related disorders. SNCA variation has also been associated with phenotypes reported in cohorts from Framingham Heart Study and other population studies.

Pathogenic mechanisms in synucleinopathies

Pathogenic mechanisms center on misfolding, oligomerization, and amyloid-like fibrillization of alpha-synuclein producing toxic species that impair synaptic function, mitochondrial integrity, and axonal transport; these pathways were delineated in experiments by groups at Rockefeller University, Institut Pasteur, and Broad Institute. Post-translational modifications—phosphorylation at serine-129, nitration, truncation, and ubiquitination—modulate aggregation propensity and clearance, findings reported by laboratories at University of California, San Diego and Weill Cornell Medicine. Evidence for prion-like cell-to-cell transmission of misfolded alpha-synuclein stems from experimental paradigms developed by teams at University of Helsinki and Mayo Clinic showing templated seeding and propagation across neural networks.

Animal and cellular models

A wide array of models supports mechanistic and preclinical studies: transgenic mice overexpressing wild-type or mutant SNCA created in labs at Jackson Laboratory and Harvard Medical School recapitulate motor deficits and synuclein pathology; viral-vector models developed by groups at University of Pennsylvania allow region-specific overexpression. Alpha-synuclein preformed fibril seeding models pioneered by researchers at Rockefeller University produce progressive Lewy-like pathology. Cellular models include primary neuronal cultures, induced pluripotent stem cell–derived neurons from patients generated in consortia including Stem Cell Institute and gene-edited lines from teams at University of California, Berkeley used to study aggregation, trafficking and toxicity.

Therapeutic approaches and biomarkers

Therapeutic strategies targeting alpha-synuclein include antisense oligonucleotides, immunotherapies (active and passive vaccines), small-molecule aggregation inhibitors, and gene-silencing approaches pursued in clinical programs at companies and academic centers linked to Biogen, Roche, AstraZeneca, Michael J. Fox Foundation collaborations. Biomarker efforts measuring alpha-synuclein in cerebrospinal fluid, plasma, and using seed amplification assays were advanced by consortia involving EU Joint Programme—Neurodegenerative Disease Research and clinical centers such as Mayo Clinic and University College London. Imaging ligands, neurophysiological markers, and multimodal biomarker panels remain active areas of translational research in trials coordinated by networks including Parkinson's Progression Markers Initiative.

Category:Genes on human chromosome 4 Category:Parkinson's disease proteins